Publications by authors named "W E Drane"
We present 8-year follow-up on the first patient with stage 4 ameloblastoma carrying a BRAF V600E mutation treated with dual BRAF/MEK inhibition (BRAF/MEKi). He experienced a durable clinical response while on dabrafenib (BRAFi) and trametinib (MEKi) without toxicity nor evidence for drug-resistant tumor progression. He was asymptomatic when he self-discontinued therapy after 4 years of sustained clinical response.
View Article and Find Full Text PDFProgrammed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors induce tumor response by activating the patient's own immune system to fight cancer. Tumors with high tumor mutational burden or those that express high levels of PD-1/PD-L1 are more responsive to PD1/PDL1 inhibitors. There is much interest in determining how to improve response to PD-1/PD-L1 inhibitors.
View Article and Find Full Text PDFArticle Synopsis
- Study aimed to evaluate the effectiveness of a standardized PET-CT program 12 weeks post-radiotherapy for patients with N2 squamous cell carcinoma of the oropharynx to determine the necessity of neck dissection.
- Among 50 patients, the PET-CT's ability to detect residual disease showed 0% sensitivity and a 91% negative predictive value, indicating it was good at ruling out the need for further surgery.
- The study concluded that a negative PET-CT can be a reliable indicator that neck dissection is unnecessary, as most recurrences occur over a year later, with a low success rate for salvage treatment.